Farletuzumab ecteribulin

DB18857InvestigationalProtein Based Therapies

Farletuzumab ecteribulin is under investigation in clinical trial NCT04300556 (A Study to Evaluate the Safety, Tolerability, and Efficacy of Morab-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha...

Mechanism: Pharmacologically active on Folate receptor alpha
Curator reviewed
Also known as: Eribulin/farletuzumab antibody drug conjugate
Code names: BMS-986445 · MORAb-202

Resolves to

Compound

UNIIUVG3B5TZN3CAS2407465-18-1

Targets

P15328FOLR1

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Farletuzumab ecteribulin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account